Domainex announces the expansion of its assay services and the launch of its unique fragment-based screening collection.

Cambridge, UK, 6th January 2012. Domainex Ltd., the UK-based fully integrated drug discovery company focused on speed and innovation, has significantly increased its discovery service capabilities, to include assay development and fragment-based screening. This expansion enables Domainex to screen small molecule compounds against a variety of enzymatic and protein-protein interaction targets, using both biochemical and biophysical assay techniques. Domainex is able to utilise its in silico LeadBuilder technology to identify hits and has invested in the establishment of a new and unique collection of chemical fragments to provide its clients with a diverse range of starting points for discovery programs. The fragment collection has considerable advantages over other commercially-available collections of fragments, as it contains a more diverse range of pharmacophores without any increase in lipophilicity. The consequence of this is that Domainex’s fragment collection is likely to reveal more potent hits than alternative collections and hits that can be developable in the absence of an x-ray crystal structure. Domainex offers fully integrated services in drug discovery which include molecular biology, including its patented Combinatorial Domain Hunting technology; protein purification and characterisation; assay development; hit identification; computational chemistry and medicinal chemistry. Domainex’s track record of delivery is superb, already resulting in five candidate drugs for clients, three of which have entered clinical trials. Dr Joanne McCudden, Head of Business Development at Domainex said: “The addition of increased capacity and expansion of Domainex’s

capabilities in assay development and small molecule screening, offers our clients a new and efficient way of finding hits against their drug targets. Domainex’s fragment-based screening is particularly powerful when coupled with Domainex’s unique protein expression capability, which enables the rapid cloning of target proteins including those which can otherwise be difficult. Domainex can now take a target through to a hit within a few months in a very cost-effective way. Exactly what drug discovery companies of all sizes need in the present demanding environment”.

• For more information see: www.domainex.co.uk or contact: Joanne McCudden Head of Business Development Joanne.mccudden@domainex.co.uk Tel +44 (0)1993 201 801

Discovery Platform | Research Pipeline | Discovery Services | About Us 162 Cambridge Science Park, Cambridge, CB4 0GH

www.domainex.co.uk